US 11,701,376 B2
Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
Rachael Buck, Gahanna, OH (US); Debra Thomas, Columbus, OH (US); and Joseph Schaller, Reynoldsburg, OH (US)
Assigned to ABBOTT LABORATORIES, Abbott Park, IL (US)
Filed by ABBOTT LABORATORIES, Abbott Park, IL (US)
Filed on Oct. 23, 2020, as Appl. No. 17/78,239.
Application 17/078,239 is a continuation of application No. 15/707,477, filed on Sep. 18, 2017, granted, now 10,813,940.
Application 15/707,477 is a continuation of application No. 13/335,404, filed on Dec. 22, 2011, granted, now 9,763,970, issued on Sep. 19, 2017.
Claims priority of provisional application 61/551,758, filed on Oct. 26, 2011.
Claims priority of provisional application 61/428,866, filed on Dec. 31, 2010.
Prior Publication US 2021/0038620 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A61K 31/708 (2006.01); A23L 33/00 (2016.01); A23L 33/13 (2016.01); A61K 31/7068 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61P 1/12 (2006.01); A23L 33/125 (2016.01); A61P 31/12 (2006.01)
CPC A61K 31/702 (2013.01) [A23L 33/125 (2016.08); A23L 33/13 (2016.08); A23L 33/40 (2016.08); A61K 31/708 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61P 1/12 (2018.01); A61P 31/12 (2018.01); A23V 2002/00 (2013.01); A23V 2200/32 (2013.01); A23V 2200/3202 (2013.01); A23V 2200/324 (2013.01); A23V 2250/284 (2013.01); A61K 2300/00 (2013.01)] 20 Claims
 
1. A synthetic pediatric formula comprising
from about 40 mg/L to about 350 mg/L of at least one of cytidine 5′-monophosphate, uridine 5′-monophosphate, adenosine 5′-monophosphate, guanosine 5′-monophosphate, and combinations thereof;
from about 0.01 mg/mL to about 10 mg/mL of at least one of 3′-sialylactose and 6′-sialylactose;
at least one of docosahexaenoic acid and arachidonic acid; and
at least one of lutein, beta-carotene, zeaxanthin, and lycopene;
wherein the synthetic pediatric formula is shelf stable for at least three months.